Pacific Capital Partners Ltd Cuts Stake in Standard BioTools Inc. $LAB

Pacific Capital Partners Ltd lowered its stake in shares of Standard BioTools Inc. (NASDAQ:LAB) by 64.2% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 475,000 shares of the company’s stock after selling 850,000 shares during the period. Pacific Capital Partners Ltd’s holdings in Standard BioTools were worth $608,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in the stock. Casdin Capital LLC raised its position in Standard BioTools by 1.9% in the third quarter. Casdin Capital LLC now owns 77,558,856 shares of the company’s stock worth $100,827,000 after acquiring an additional 1,483,220 shares during the period. Vanguard Group Inc. grew its position in shares of Standard BioTools by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 17,245,583 shares of the company’s stock valued at $22,419,000 after acquiring an additional 263,845 shares during the period. Mak Capital One LLC increased its stake in shares of Standard BioTools by 184.6% during the 3rd quarter. Mak Capital One LLC now owns 15,931,806 shares of the company’s stock worth $20,711,000 after purchasing an additional 10,334,384 shares during the last quarter. Long Focus Capital Management LLC raised its holdings in shares of Standard BioTools by 12.8% in the 3rd quarter. Long Focus Capital Management LLC now owns 11,362,804 shares of the company’s stock worth $14,772,000 after purchasing an additional 1,292,804 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Standard BioTools by 3.3% in the 2nd quarter. Geode Capital Management LLC now owns 7,441,134 shares of the company’s stock worth $8,931,000 after purchasing an additional 235,677 shares during the period. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Standard BioTools Stock Up 2.7%

NASDAQ LAB opened at $0.92 on Tuesday. The firm has a market cap of $359.49 million, a P/E ratio of -4.61 and a beta of 1.36. The company’s 50 day moving average is $1.16 and its 200-day moving average is $1.29. Standard BioTools Inc. has a 12-month low of $0.88 and a 12-month high of $1.72.

Standard BioTools (NASDAQ:LAB) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.08. Standard BioTools had a negative net margin of 59.39% and a negative return on equity of 11.21%. The business had revenue of $23.80 million during the quarter, compared to analyst estimates of $18.50 million. Equities analysts expect that Standard BioTools Inc. will post -0.29 EPS for the current year.

Analysts Set New Price Targets

LAB has been the subject of several research reports. Wall Street Zen raised Standard BioTools from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Zacks Research upgraded Standard BioTools to a “hold” rating in a research note on Thursday, December 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Standard BioTools in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $1.35.

About Standard BioTools

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.